Compare
Nexentis Technologies Inc. vs Evofem Biosciences, Inc. vs Emmaus Life Sciences, Inc. vs Phio Pharmaceuticals Corp.
| Latest fiscal year | Nexentis Technologies Inc. NXTS | Evofem Biosciences, Inc. EVFM | Emmaus Life Sciences, Inc. EMMA | Phio Pharmaceuticals Corp. PHIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $20.18M | $12.45M | n/a |
| Revenue growth (YoY) | n/a | +4.2% | -25.2% | n/a |
| Gross margin | n/a | 77.1% (computed) | 93.1% | n/a |
| Operating margin | n/a | 16.7% | 1.9% | n/a |
| Net margin | n/a | 1.9% | -60.2% | n/a |
| Net income | -$4.00M | $391.0K | -$7.49M | -$8.70M |
| EPS (Diluted) | -$8.61 | $0.00 | -$0.12 | n/a |
| Operating cash flow | -$3.81M | -$1.99M | -$11.0K | -$7.98M |
| Free cash flow | -$3.82M | -$2.00M | -$12.0K | -$7.99M |
| Cash & equivalents | $3.83M | $578.0K | $2.13M | $21.03M |
| Total assets | $20.41M | $20.27M | $21.44M | $21.49M |
| Total liabilities | $4.67M | $89.71M | $85.04M | $1.34M |
| Shareholders' equity | $16.01M | -$74.34M | -$63.61M | $20.15M |
| Return on year-end equity | -25.0% | n/a | n/a | -43.2% |
| Shares outstanding | 2.77M | 126.69M | 70.19M | 11.62M |
Revenue, most recent five fiscal years
| Fiscal year | Nexentis Technologies Inc. | Evofem Biosciences, Inc. | Emmaus Life Sciences, Inc. | Phio Pharmaceuticals Corp. |
|---|---|---|---|---|
| Latest | $210.0K Ended 2024-12-31 | $20.18M Ended 2025-12-31 | $12.45M Ended 2025-12-31 | $0 Ended 2020-12-31 |
| 1 year earlier | $263.0K Ended 2023-12-31 | $19.36M Ended 2024-12-31 | $16.65M Ended 2024-12-31 | $21.0K Ended 2019-12-31 |
| 2 years earlier | $394.0K Ended 2022-12-31 | $18.22M Ended 2023-12-31 | $29.60M Ended 2023-12-31 | $138.0K Ended 2018-12-31 |
| 3 years earlier | $438.1K Ended 2021-12-31 | $16.84M Ended 2022-12-31 | $18.39M Ended 2022-12-31 | $15.0K Ended 2017-12-31 |
| 4 years earlier | $232.3K Ended 2020-12-31 | $8.24M Ended 2021-12-31 | $20.61M Ended 2021-12-31 | $19.0K Ended 2016-12-31 |